# GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Canonical URL: https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-of-differentiated-immune-modulating-pipeline
Ticker: GRI
Company: GRI Bio
Source: GRI Bio
Published: 2026-05-14 08:35 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><i>Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm - suggesting GRI-0621 may mitigate ni

## Article Body
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm - suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination

Advancing GRI-0803 toward IND-enabling activities to expand the pipeline across autoimmune...
## Recent Company News
- 2026-05-14 08:35 EST — [GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline](https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-of-differentiated-immune-modulating-pipeline) — Source: GRI Bio
- 2026-04-08 08:30 EST — [GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions](https://biopharmsignal.com/news/GRI/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions) — Source: GRI Bio
- 2026-02-17 09:15 EST — [GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment](https://biopharmsignal.com/news/GRI/gri-bio-ceo-marc-hertz-featured-in-virtual-investor-what-this-means-segment) — Source: GRI Bio
- 2026-02-05 09:15 EST — [GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial](https://biopharmsignal.com/news/GRI/gri-bio-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial) — Source: GRI Bio
- 2026-02-04 08:45 EST — [GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights](https://biopharmsignal.com/news/GRI/gri-bio-reiterates-full-year-2025-financial-results-strengthens-balance-sheet-and-summarizes-key-recent-highlights) — Source: GRI Bio
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-na&#239;ve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)